Literature DB >> 2464361

A rapid and simple colorimetric test for the study of anti-HIV agents.

O Schwartz1, Y Henin, V Marechal, L Montagnier.   

Abstract

We report here the use of a simple, rapid, reproducible, and quantitative assay to detect the putative activity of anti-HIV agents. It can be employed with different T cell cultures, such as peripheral blood lymphocytes or CEM-C113 cells, a sensitive clone of CEM cells. It can be used alone as a rapid screening test in order to measure both cytotoxicity and the potential antiviral activity of large numbers of compounds. It can also be combined for thorough studies with other classic tests that detect virus production. Among these tests, a micro-method to measure reverse transcriptase activity is shown to be very useful. To illustrate the practicability of the assay, 3'-azido-2',3'-dideoxythymidine (AZT) and ribavirin are studied.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464361     DOI: 10.1089/aid.1988.4.441

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  29 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Simple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4.

Authors:  V Chams; T Idziorek; P J Maddon; D Klatzmann
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

Authors:  P J Yates; R Hazen; M St Clair; L Boone; M Tisdale; R C Elston
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

5.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.

Authors:  S Le Borgne; M Février; C Callebaut; S P Lee; Y Rivière
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein.

Authors:  A Erice; H H Balfour; D E Myers; V L Leske; K J Sannerud; V Kuebelbeck; J D Irvin; F M Uckun
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

Authors:  J F Mayaux; A Bousseau; R Pauwels; T Huet; Y Hénin; N Dereu; M Evers; F Soler; C Poujade; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.